Key result
Duloxetine use was associated with the precipitation of tako-tsubo cardiomyopathy in a 68-year-old woman, potentially by increasing plasma catecholamine concentrations.
Why the study?
Does duloxetine use precipitate 'tako-tsubo' cardiomyopathy in predisposed patients?
Case Report (n=1)
Does duloxetine use precipitate 'tako-tsubo' cardiomyopathy in predisposed patients?
Duloxetine, a serotonin and norepinephrine reuptake inhibitor, may precipitate 'tako-tsubo' cardiomyopathy by increasing plasma catecholamines in predisposed patients.
May warrant monitoring for Takotsubo cardiomyopathy with duloxetine in at-risk patients; single case leaves open causality and need for confirmation.
We report the case of a 68-year-old woman in whom the use of duloxetine, a potent serotonin and norepinephrine reuptake inhibitor, was associated with "tako-tsubo" cardiomyopathy (TTC). Although several pathophysiological mechanisms for TTC have been proposed, available evidence suggests that an excess of catecholamines may play a major role. Our patient had a history of myocardial infarction with normal coronary arteries, probably the first manifestation of TTC. We speculate that duloxetine may have precipitated TTC by increasing plasma catecholamine concentration in a predisposed patient.
No takes yet. Share an insight, caveat, or question.
Rotondi et al. (2011) conducted a case report in Tako-tsubo cardiomyopathy (n=1). Duloxetine was evaluated on Tako-tsubo cardiomyopathy. Duloxetine use was associated with the precipitation of tako-tsubo cardiomyopathy in a 68-year-old woman, potentially by increasing plasma catecholamine concentrations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: